Rutgers Institut(e)ing for Personalized Medicine - Office of Organizational Leadership Skip to main content

Rutgers Institut(e)ing for Personalized Medicine

Hatem E. Sabaawy, MBBCh, MD, PhD
Associate Professor of Medicine and Pathology and Laboratory Medicine
Rutgers Cancer Institute of NJ and Department of Medicine, RBHS/RWJMS

Hatem Sabaawy is Associate Professor of Medicine and Pathology, Associate Director of Biorepository, Director of PDX/PDO at Rutgers Cancer Institute. He joined RWJMS after graduating from New York Medical College and completing NCI fellowship. He has been an NIH-funded investigator and his research received funding from DOD, NSF, and foundations. He serves on multiple editorial boards, three NIH special emphasis panels, and international French ANR, British Innovation Fund, and Australian agencies. He has mentored dozens of students, residents, fellows, and directs Genomics in Cancer Therapeutics GSBS course. He is a passionate educator and strong advocate for investing in people.

Project Sponsors
Andrea Conklin Bueschel, PhD
Chief of Staff and Senior Vice President for Administration
Office of the President

Bishr Omary, MD
Senior Vice Chancellor for Academic Affairs and Research

Personalized medicine is the use of individual characteristics to tailor treatments. Precision medicine is the form of personalized medicine and our research focus at the Cancer Institute. We utilize the genomic profiles of every patient to find innovative ways for cancer diagnosis, monitoring, and treatment. We recognize a presented opportunity to extend this personalized medicine approach to other chronic, complex diseases, including diabetes, heart disease, depression, and autoimmune disorders. This approach would allow to treat each patient based on genetic, phenotypic, or psychosocial characteristic to improve health and presentive cares.

The project is aimed at expanding personalized medicine to many aspects of the higher education training and various healthcare enterprises. The mission of personalized medicine will be multidisciplinary in applying genomic technologies to improve the way diseases are detected, monitored, treated, and prevented. Implementation will be a stepwise process and started by surveying and inviting key stakeholders to form committees for integrating existing resources, proposing medical and graduate school courses in the following academic years, arranging seminar series including different University campuses, and working with the RBHS administration to identify philanthropic sponsors and industry collaborators. This effort will bring together data scientists, engineers, biologists, social scientists, and cancer precision medicine experts in thinktanks to develop funding proposals focused on single cell assays, functional research in animal and human tissue models, and applications in clinical medicine.